Mylan and Biocon’s Semglee Receives EU Approval for Patients with Diabetes

 Mylan and Biocon’s Semglee Receives EU Approval for Patients with Diabetes

Mylan Voluntary Globally Recalls 2 Lots of Levoleucovorin (250mg/25ml) Injection Used to Prevent Harmful Effects of Methotrexate

Shots:

  • The approval is based on CHMP (EMA) recommendation, reviewed by EU for diabetic patients
  • In 2009, Mylan and Biocon globally collaborated to jointly develop multiple generic biologic compounds
  • Semglee is a prefilled 100unit/ml 3ml disposable pen, approved in Australia by TGA and in EU including Norway, Iceland and Liechtenstein for patients with diabetes with its expected launch in H2’18

Click here read full press release/ article | Ref: Mylan | Image: Medical News

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post